Tegafur
- Generic Name
- Tegafur
- Brand Names
- Teysuno
- Drug Type
- Small Molecule
- Chemical Formula
- C8H9FN2O3
- CAS Number
- 17902-23-7
- Unique Ingredient Identifier
- 1548R74NSZ
- Background
Tegafur (INN, BAN, USAN) is a prodrug of Fluorouracil (5-FU), an antineoplastic agent used as the treatment of various cancers such as advanced gastric and colorectal cancers. It is a pyrimidine analogue used in combination therapies as an active chemotherapeutic agent in conjunction with Gimeracil and Oteracil, or along with Fluorouracil as Tegafur-uracil. ...
- Indication
Indicated for the treatment of cancer usually in combination with other biochemically modulating drugs.
Indicated in adults for the treatment of advanced gastric cancer when given in combination with Cisplatin .
Indicated for the first-line treatment of metastatic colorectal cancer with Uracil and calcium folinate .
- Associated Conditions
- Stage IV Gastric Cancer
- Associated Therapies
- -
Apapitatin Combined With SOX for Palliative Adjuvant Chemotherapy in Patients With Advanced Gallbladder Carcinoma
- First Posted Date
- 2018-10-11
- Last Posted Date
- 2018-10-11
- Lead Sponsor
- Eastern Hepatobiliary Surgery Hospital
- Target Recruit Count
- 138
- Registration Number
- NCT03702491
- Locations
- 🇨🇳
xiao qing xiao qing Jiang, Shanghai, Shanghai, China
Phase II Randomized Trial of SLOG vs GC in Locally Advanced or Metastatic Biliary Tract Cancer
- Conditions
- Interventions
- First Posted Date
- 2018-01-23
- Last Posted Date
- 2024-07-05
- Lead Sponsor
- National Health Research Institutes, Taiwan
- Target Recruit Count
- 92
- Registration Number
- NCT03406299
- Locations
- 🇨🇳
Taiwan Cooperative Oncology Group, National Health Research Institutes, Taipei, Taiwan
A Study of Tegafur Combined With Temozolomide Versus Tegafur Combined With Temozolomide and Thalidomide in Subjects With Advanced Extrapancreatic Neuroendocrine Tumor
- Conditions
- Interventions
- First Posted Date
- 2017-06-29
- Last Posted Date
- 2017-06-29
- Lead Sponsor
- Chinese Academy of Medical Sciences
- Target Recruit Count
- 60
- Registration Number
- NCT03204032
- Locations
- 🇨🇳
Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Beijing, Beijing, China
Adoptive Transfer of iNKT Cells for Treating Patients With Relapsed/Advanced HCC
- First Posted Date
- 2017-06-05
- Last Posted Date
- 2018-01-18
- Lead Sponsor
- Beijing YouAn Hospital
- Target Recruit Count
- 18
- Registration Number
- NCT03175679
- Locations
- 🇨🇳
Beijing Youan Hospital,Capital Medical University, Beijing, Beijing, China
Adoptive Transfer of Specific HCC Antigens CD8+ T Cells for Treating Patients With Relapsed/Advanced HCC
- Conditions
- Interventions
- First Posted Date
- 2017-06-05
- Last Posted Date
- 2018-01-18
- Lead Sponsor
- Beijing YouAn Hospital
- Target Recruit Count
- 18
- Registration Number
- NCT03175705
- Locations
- 🇨🇳
Beijing Youan Hospital,Capital Medical University, Beijing, Beijing, China
Combination Chemotherapy in Treating Patients With Resected Colon Cancer
- Conditions
- Interventions
- First Posted Date
- 2006-09-21
- Last Posted Date
- 2010-01-11
- Lead Sponsor
- NSABP Foundation Inc
- Target Recruit Count
- 1608
- Registration Number
- NCT00378716
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.